Article ; Online: Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial.
2023 Volume 31, Issue 2, Page(s) 466–478
Abstract: Objective: Colchicine is known to reduce inflammation and improve endothelial cell function and atherosclerosis in obesity, but there is little knowledge of the specific circulating leukocyte populations that are modulated by colchicine.: Methods: A ... ...
Abstract | Objective: Colchicine is known to reduce inflammation and improve endothelial cell function and atherosclerosis in obesity, but there is little knowledge of the specific circulating leukocyte populations that are modulated by colchicine. Methods: A secondary analysis of a double-blind randomized controlled trial of colchicine 0.6 mg or placebo twice daily for 3 months on circulating leukocyte populations and regulation of the immune secretome in 35 adults with obesity was performed. Results: Colchicine altered multiple innate immune cell populations, including dendritic cells and lymphoid progenitor cells, monocytes, and natural killer cells when compared with placebo. Among all subjects and within the colchicine group, changes in natural killer cells were significantly positively associated with reductions in biomarkers of inflammation, including cyclooxygenase 2, pulmonary surfactant-associated protein D, myeloperoxidase, proteinase 3, interleukin-16, and resistin. Changes in dendritic cells were positively correlated with changes in serum heart-type fatty acid-binding protein concentrations. Additionally, colchicine treatment reduced cluster of differentiation (CD) CD4+ T effector cells and CD8+ T cytotoxic cells. Conversely, colchicine increased CD4+ and CD8+ T central memory cells and activated CD38 Conclusions: In adults with obesity, colchicine significantly affects circulating leukocyte populations involved in both innate and adaptive immune systems along with the associated inflammatory secretome. |
---|---|
MeSH term(s) | Adult ; Humans ; Colchicine/pharmacology ; Colchicine/therapeutic use ; Leukocytes, Mononuclear ; Obesity/complications ; Inflammation/metabolism ; Fatty Acid-Binding Proteins/therapeutic use |
Chemical Substances | Colchicine (SML2Y3J35T) ; Fatty Acid-Binding Proteins |
Language | English |
Publishing date | 2023-01-11 |
Publishing country | United States |
Document type | Randomized Controlled Trial ; Journal Article ; Research Support, N.I.H., Intramural |
ZDB-ID | 2230457-5 |
ISSN | 1930-739X ; 1071-7323 ; 1930-7381 |
ISSN (online) | 1930-739X |
ISSN | 1071-7323 ; 1930-7381 |
DOI | 10.1002/oby.23632 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4061: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MG 87: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.